Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up
- 83 Downloads
Although well-documented from pathological aspect, the clinical features and outcomes of acromegaly with mammosomatotroph (MSA) and mixed somatotroph-lactotroph adenoma (MSLA) are seldom reported. Thus, in this study, we analyzed and reported the clinical data about MSAs and MSLAs.
We retrospectively reviewed medical records of patients with acromegaly in our institution during 2008–2017. Growth hormone (GH)-secreting adenomas were categorized into pure somatotroph adenoma (PSA), MSA and MSLA based on inclusion and exclusion criteria. Clinical information and treatment outcomes during follow-up were analyzed by univariate and multivariate methods.
Among 94 patients within this cohort, PSAs, MSAs, and MSLAs accounted for 53, 28 and 13 cases, respectively. MSAs often had smaller size, lower frequency of cavernous sinus invasion and higher gross total resection (GTR) rate. MSLAs were characterized by bigger tumor size, higher frequency of preoperative hyperprolactinemia, and lower GTR rate. Thus, MSLAs had worse long-term biological remission rate than MSAs and PSAs (15.4% vs. 50.0% and 26.4%, p = 0.0371). Gender (male, OR = 0.784, p = 0.011) and tumor volume (OR = 0.784, p = 0.020) were independent predictors for long-term biological remission in binary logistic regression. Subgroup analyses indicated that postoperative nadir GH level (GH-7, HR = 1.242, p = 0.001) was the only risk factor for tumor recurrence for patients with GTR.
Our results provide valuable insights into clinicopathological features of acromegaly. MSAs were relatively smaller lesions with better prognosis. MSLAs were more aggressive with massive size, invasiveness and preoperative hyperprolactinemia. Tumor size and GH-7 were significantly associated with biological remission and tumor relapse after GTR, respectively.
KeywordsAcromegaly Mammosomatotroph adenoma Mixed somatotroph-lactotroph adenoma Remission
This research was financially supported by the Foundation of Science and Technology Department of Sichuan Province (Grant No. 2018SZ0179 and Grant No. 2016SZ0015).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by Biomedical Research Ethics Committee of West China Hospital of Sichuan University.
For this type of study formal consent is not required.
- 1.D. Esposito, O. Ragnarsson, D. Granfeldt, T. Marlow, G. Johannsson, D.S. Olsson, Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur. J. Endocrinol. 178, 459–469 (2018)Google Scholar
- 9.L. Vilar, M. Fleseriu, L.A. Naves, J.L. Albuquerque, P.S. Gadelha, M. dos Santos Faria, G.C. Nascimento, R.M. Montenegro Jr., R.M. Montenegro, Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial. Endocrine 46(3), 577–584 (2014). https://doi.org/10.1007/s12020-013-0094-9 CrossRefPubMedGoogle Scholar
- 12.N. Mohammed, D. Ding, Y.-C. Hung, Z. Xu, C.-C. Lee, H. Kano, R. Martínez-Álvarez, N. Martínez-Moreno, D. Mathieu, M. Kosak, C. P. Cifarelli, G. A. Katsevman, L. D. Lunsford, M. L. Vance, J. P. Sheehan, Primary versus postoperative stereotactic radiosurgery for acromegaly: a multicenter matched cohort study. 1 (2019). https://doi.org/10.3171/2019.1.jns183398
- 18.J. Rick, A. Jahangiri, P.M. Flanigan, A. Chandra, S. Kunwar, L. Blevins, M. K. Aghi, Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes. J. Neurosurg. 1–7 (2018). https://doi.org/10.3171/2018.4.JNS18230 CrossRefGoogle Scholar
- 20.P. Andujar-Plata, R. Villar-Taibo, M.D. Ballesteros-Pomar, A. Vidal-Casariego, B. Perez-Corral, J.M. Cabezas-Agricola, P. Alvarez-Vazquez, R. Serramito, I. Bernabeu, Long-term outcome of multimodal therapy for giant prolactinomas. Endocrine 55(1), 231–238 (2017). https://doi.org/10.1007/s12020-016-1129-9 CrossRefPubMedGoogle Scholar
- 24.K. Kiseljak-Vassiliades, N.E. Carlson, M.T. Borges, B.K. Kleinschmidt-DeMasters, K.O. Lillehei, J.M. Kerr, M.E. Wierman, Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49(1), 231–241 (2015). https://doi.org/10.1007/s12020-014-0383-y CrossRefPubMedGoogle Scholar
- 27.V. De Sanctis, H. Elsedfy, A.T. Soliman, I.Z. Elhakim, N.A. Soliman, M. Karimi, R. Elalaily, The diagnostic approach to central adrenocortical insufficiency (CAI) in thalassemia. Mediterr. J. Hematol. Infect. Dis. 8(1), e2016026 (2016). https://doi.org/10.4084/MJHID.2016.026 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.U. Boehm, P.M. Bouloux, M.T. Dattani, N. de Roux, C. Dode, L. Dunkel, A.A. Dwyer, P. Giacobini, J.P. Hardelin, A. Juul, M. Maghnie, N. Pitteloud, V. Prevot, T. Raivio, M. Tena-Sempere, R. Quinton, J. Young, Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism–pathogenesis, diagnosis and treatment. Nature reviews. Endocrinology 11(9), 547–564 (2015). https://doi.org/10.1038/nrendo.2015.112 CrossRefPubMedGoogle Scholar
- 29.S.C. Dogansen, G.Y. Yalin, S. Tanrikulu, S. Tekin, N. Nizam, B. Bilgic, S. Sencer, S. Yarman, Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary 21(4), 347–354 (2018). https://doi.org/10.1007/s11102-018-0877-3 CrossRefPubMedGoogle Scholar
- 33.N. Karavitaki, G. Thanabalasingham, H.C. Shore, R. Trifanescu, O. Ansorge, N. Meston, H.E. Turner, J.A. Wass, Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin. Endocrinol. (Oxf.) 65(4), 524–529 (2006). https://doi.org/10.1111/j.1365-2265.2006.02627.x CrossRefGoogle Scholar
- 34.M.V. Smith, E.R. Laws Jr., Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: lack of correlation with serum prolactin levels. Neurosurgery 34(5), 834–839 (1994). discussion 839.PubMedGoogle Scholar
- 36.M. P. Salomon, X. Wang, D. Marzese, S. C. Hsu, N. Nelson, Z. Xin, C. Matsuba, Y. Takasumi, C. Ballesterosmerino, B. A. Fox, The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, Cushing’s disease and endocrine-inactive subtypes. Clin. Cancer Res. 24(17), 4126–4136 (2018)CrossRefGoogle Scholar
- 40.L. Lv, Y. Hu, P. Zhou, S. Zhang, S. Yin, N. Zhang, S. Jiang, Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: a long-term single-center experience. Clin. Neurol. Neurosurg. 167, 24–30 (2018). https://doi.org/10.1016/j.clineuro.2018.02.006 CrossRefPubMedGoogle Scholar
- 42.M. Sherlock, R.C. Reulen, A. Aragon-Alonso, J. Ayuk, R.N. Clayton, M.C. Sheppard, M.M. Hawkins, A.S. Bates, P.M. Stewart, A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J. Clin. Endocrinol. Metab. 99(2), 478–485 (2014). https://doi.org/10.1210/jc.2013-2450 CrossRefPubMedGoogle Scholar
- 43.L. Lv, S. Zhang, Y. Hu, P. Zhou, L. Gao, M. Wang, Z. Sun, C. Chen, S. Yin, X. Wang, S. Jiang, Invasive pituitary adenoma-derived tumor-associated fibroblasts promote tumor progression both in vitro and in vivo. Exp. Clin. Endocrinol. Diabetes (2017). https://doi.org/10.1055/s-0043-119636 CrossRefGoogle Scholar